(Q45377956)

13 December 2017

0 references

1 reference

title

Role of the cholinesterase inhibitors in the treatment of schizophrenia (English)

1 reference

13 December 2017

0 references

Chi-Un Pae

1

1 reference

13 December 2017

language of work or name

English

0 references

publication date

21 January 2013

1 reference

Expert Opinion on Investigational Drugs

13 December 2017

published in

1 reference

13 December 2017

volume

22

1 reference

13 December 2017

issue

3

1 reference

13 December 2017

page(s)

293-298

1 reference

Treating schizophrenia: novel targets for the cholinergic system

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Drug targets for cognitive enhancement in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Schizophrenia and the alpha7 nicotinic acetylcholine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Nicotinic receptor subunit mRNA in the thalamus of the rat: relevance to schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Cognitive impairment as a target for pharmacological treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Cholinergic circuits and signaling in the pathophysiology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Role of the cholinergic system in the pathology and treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Postmortem studies in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Cholinesterase inhibitors: A new class of psychotropic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Galantamine for the treatment of cognitive impairments in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

The treatment of cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.762355

10.1517/13543784.2013.762355

21 January 2018

Identifiers

DOI

1 reference

13 December 2017

1 reference